NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Inclusion Criteria: * Patients with histologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external-beam fractionated radiotherapy and temozolomide chemotherapy. * Patients with up to two prior recurrences are allowed. * Karnofsky performance status ≥70. * Patients must have the following laboratory values: * Absolute neutrophil count (ANC) ≥1.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Hemoglobin (Hgb) \> 9 g/dL * Serum total bilirubin: ≤ 1.5 x ULN * ALT and AST ≤ 3.0 x ULN * Serum creatinine ≤ 1.5 x ULN * Blood coagulation parameters: INR ≤ 1.5 * Minimum interval since completion of radiation treatment is 12 weeks * Minimum interval since last drug therapy: * 3 weeks since last non-cytotoxic therapy * 3 weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen * 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen. * Patients must have signed an approved informed consent and authorization permitting release of personal health information. * Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. The effects of bevacizumab on developing fetus or nursing infant are not known. Female patients of child-bearing potential must have a negative pregnancy test. * Patients must have no concurrent malignancy except curati…